Considering the multitude of evidence supporting SIRT1's neuroprotective potential against PD and the dynamic range of mechanisms in which that protection is enacted, SIRT1 appears to be an optimal target for the therapeutic treatment of PD. The gene discussed is SIRT1; the disease is Parkinson disease.